PTPentti J. Tienari

Pentti J. Tienari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pentti J. Tienari has a total of 402 co-authors. Here are the top co-authors by number of shared publications:

  • John Hardy

    Reta Lila Weston Research Laboratories, Departments of Molecular Neuroscience and of Clinical Neuroscience, UCL Institute of Neurology Queen Square, London, United Kingdom

    5 shared publications
  • Karri Kaivola

    Translational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland

    5 shared publications
  • Liisa Myllykangas

    Department of Pathology, Medicum, University of Helsinki, Helsinki, Finland

    5 shared publications
  • Lilja Jansson

    Translational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland

    5 shared publications
  • Minna Oinas

    Department of Pathology, University of Helsinki, Helsinki, Finland

    4 shared publications
  • Raimo Sulkava

    School of Public Health and Clinical Nutrition, University of Eastern Finland Kuopio, Finland

    4 shared publications

Latest Publications

  • Open Access

    Intergenerational instability of the C9orf72 hexanucleotide repeat

    by Osma S. Rautila, Anna Kiviharju, Lilja Jansson, Finn Gen, Karri Kaivola, Pentti J. Tienari

    The C9orf72 hexanucleotide repeat expansion (HRE) is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). It follows autosomal dominant inheritance in families; however, a high proportion of cases are sporadic, raising the possibility of parental premutation. We have demon strated that intermediatelength alleles (IAs) with ≥ 18 repeats (allele frequency ≈1%) belong to the same pool of haplotypes as the HRE, suggesting shared ancestry. Here, we tested whether alleles with ≥ 18 repeats expand in parental transmission. We used two repeatprimed PCR methods to analyze allele lengths in 539 genetically unselected parentoffspring pairs and in 152 pairs known to carry the SNP (rs139185008*C) that tags ≥ 18–20 repeat IAs and the HRE in Finland. We discovered intergenerational repeat length changes only in ≥ 20 repeat alleles. A significant (P = 0.0059) sex bias in 6–40 repeat alleles was noted using a logistic regression model. In this allele range, 12 out of 16 expansions were paternally inherited and 6 out of 7 contractions were maternally inherited. The expansion rate of 20–40 repeat alleles was 34 % in paternal and 11 % in maternal transmissions. In the 20–40 repeat range, most intergenerational expansions were 1–4 repeats in size (15/16), but one larger “jump”, a paternal expansion from 27 to 73 repeats, was observed. These results demonstrate that alleles with ≥ 20 repeats have an increased likelihood of instability, that a paternal expansion bias is observed in alleles with 20–40 repeats, and that expansion events are predominantly 1–4 repeats in size.

  • Open Access

    EBV genome analysis in multiple sclerosis shows extensive viral diversity and links to autoimmunity

    by Joonas Lehikoinen, Leo Hannolainen, Osma S Rautila, Zachery W Dickson, Lari Pyöriä, Liane Dieterich, Lilja Jansson, Silja Tammi, Klaus Hedman, Maria F Perdomo, et al.

    Epstein–Barr virus (EBV) is a major risk factor for multiple sclerosis (MS), yet the contribution of specific viral variants remains unclear. Complete EBV genome analysis of wild-type variants has not been performed previously. In a pilot-study, targeted EBV sequencing of B cells did not yield adequate coverages due to excess of human DNA. Thus, we developed an ex vivo 6-day leukocyte culture method to enrich EBV DNA into supernatant by stimulation with tetradecanoyl phorbol acetate. Using this method in 20 MS patients and 20 controls, we obtained near-complete EBV genomes in 9 MS patients (average coverage 97%) and in 4 controls (average 85%). We identified 1088 single-nucleotide variants (33% missense variants) outside repetitive regions that met stringent quality criteria. Overall, 94% of the variants were present in three or more subjects, thus unlikely generated during the culture and several were exclusive to MS, worth of further investigation. In silico analysis indicated that variants within the EBNA1 cross-reactive region change human leukocyte antigen (HLA) peptide binding affinity, suggesting altered antigen presentation. These results illustrate a method for enriching EBV genomes and present the first wild-type sequences from MS patients. The observed diversity highlights potential for future studies in EBV-associated diseases and vaccine development.


  • Open Access

    Tracing the origin of Finnish gelsolin amyloidosis using haplotype sharing trees

    by Osma S. Rautila, Sari Atula, Tuuli Mustonen, Eeva-Kaisa Schmidt, Miko Valori, Roberto Colombo, Juha Kere, Karri Kaivola, Pentti J. Tienari

    Finnish gelsolin amyloidosis (AGel amyloidosis) is an autosomal dominant systemic amyloidosis caused by GSN c.640G>A p.D187N (rs121909715) founder variant. The disease was first described in 1969, and it was hypothesized that the Finnish patients share a common ancestor dating back to the 14th century. The link between two Finnish regions with high AGel incidence (Kanta-Häme and Kymenlaakso) has been hypothesized to have occurred in 1365 by a settler moving from Kanta-Häme to Kymenlaakso. Here, we used haplotype sharing tree (HST) to analyze Finnish AGel amyloidosis haplotypes to trace the geographic origin of the variant. We also estimated the time from the most recent common ancestor (MRCA) using single nucleotide polymorphism and short tandem repeat data. The HST -based analyses leveraging AGel amyloidosis cohorts from different Finnish geographic regions indicated, that the variant more likely appeared first in Kymenlaakso, not Kanta-Häme, contrary to the original hypothesis. The MRCA estimates for Finnish AGel ranged from 15 to 40 generations using four different methods, the mean of all estimates (27 generations) dated back to the 14th century. Thus, the data supports the original hypothesis on the variant’s spreading temporally, but not geographically. These results illustrate the use of HSTs in the analysis of haplotype structures and in tracing the ancestry of a founder variant.

  • Open Access

    Optimized Kappa‐Index Test Protocol to Detect Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis

    by Joel Björklund, Outi Itkonen, Pasi Nokelainen, Mika Siuko, Emilia Österlund‐Tauriala, Pentti J. Tienari, Mikko Anttonen

    Background: Kappa free light chain (KFLC)‐based Kappa‐index (K‐index) can substitute oligoclonal banding (OCB) to detect intrathecal immunoglobulin synthesis. Cutoffs for positive results vary; therefore, further comparison of different approaches is necessary to optimize K‐index for diagnostic utilization. Methods: We analyzed 432 paired CSF/serum samples and selected 77 OCB‐positive patients with multiple sclerosis (MS), clinically isolated syndrome (CIS) that did not progress to MS in > 10 years, and other neuroinflammatory diseases (non‐MS). K‐index subtests were measured on the Optilite platform (The Binding Site) and OCB with isoelectric focusing on the Hydrasys platform (Sebia). Results: OCB positive cases had a higher K‐index than OCB negative. The MS group had a higher K‐index than CIS ( p = 0.0066) and non‐MS ( p < 0.0001). A K‐index over 80.9 suggests MS over CIS, and 61.4 suggests MS over non‐MS. Different values to mimic undetectable CSF KFLC levels resulted in different cutoffs against positive OCB. Using the limit of detection (LOD) of the assay and fixing sensitivity and specificity to 95% to establish the gray area, the cutoffs were < 4.45 (negative) and > 12.92 (positive). When undetectable CSF KFLC was also considered negative, specificity against OCB was 99.7% and sensitivity 92.7%, leaving 6% for gray area OCB verification testing. Conclusions: Published K‐index cutoffs vary due to different settings of CSF KFLC results below LOD. Using a reflex approach, where samples within a certain K‐index gray area are subjected to OCB verification testing, and where samples with CSF KFLC below LOD are considered negative, was the most efficient laboratory algorithm. K‐index may also have prognostic value in MS.


  • Altered immune landscape of cervical lymph nodes reveals Epstein-Barr virus signature in multiple sclerosis

    by Joona Sarkkinen, Dawit A. Yohannes, Nea Kreivi, Pia Dürnsteiner, Alexandra Elsakova, Jani Huuhtanen, Kirsten Nowlan, Goran Kurdo, Riikka Linden, Mika Saarela, et al.

    Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, and Epstein-Barr virus (EBV) infection is a prerequisite for developing the disease. However, the pathogenic mechanisms that lead to MS remain to be determined. Here, we characterized the immune landscape of deep cervical lymph nodes (dcLNs) in newly diagnosed untreated patients with MS (pwMS) using fine-needle aspirations. By combining single-cell RNA sequencing and cellular indexing of transcriptomes and epitopes by sequencing, we observed increased memory B cells and reduced germinal center B cells with decreased clonality in pwMS. Double-negative memory B cells were increased in pwMS that transcriptionally resembled B cells with a lytic EBV infection. Moreover, EBV-targeting memory CD8 T cells were detected in a subset of pwMS. We also detected increased EBV DNA in dcLNs and elevated viral loads in patient saliva. These findings suggest that EBV-driven B cell dysregulation is a critical mechanism in MS pathogenesis.


  • Open Access

    Cancer-type somatic mutations in saccular cerebral aneurysms

    by Behnam Rezai Jahromi, Miko Valori, Riikka Tulamo, Suvi Jauhiainen, Henna Ilmonen, Jonas Kantonen, Minna Kaikkonen-Määttä, Aki Laakso, Seppo Ylä-Hertuala, Juha E. Jääskeläinen, et al.

    Intracranial aneurysms (IAs) are a major cause of subarachnoidal hemorrhage (SAH) which can have a significant morbidity and mortality. The processes underlying the aneurysm development remains unclear. We performed whole exome sequencing of DNA derived from 20 saccular cerebral aneurysms of 20 patients, followed by somatic variant calling. Eleven (55%) of the 20 patients had detectable nonsynonymous somatic mutations and in total, 48 mutations were detected in the aneurysm samples. The mutations were highly enriched in cancer-related genes and 77% were predictably deleterious. A p.Tyr562Asp somatic mutation was detected in the PDGFRB gene; somatic mutations at the same codon have been reported in fusiform cerebral aneurysms. These results widen the concept on the role of somatic mutations in cerebral aneurysms, indicating their possible role in the more common saccular aneurysm, similarly to the rarer fusiform aneurysm.


  • Open Access

    Parvovirus B19 and Human Herpes Virus 6B and 7 Are Frequently Found DNA Viruses in the Human Thymus But Show No Definitive Link With Myasthenia Gravis

    by Kirsten Nowlan, Leo Hannolainen, Irini M Assimakopoulou, Pia Dürnsteiner, Joona Sarkkinen, Santeri Suokas, Lea Hedman, Pentti J Tienari, Klaus Hedman, Mikael Niku, et al.

    Myasthenia gravis (MG) is a rare autoimmune disorder characterized by muscle weakness resulting from autoantibody-mediated disruption of the neuromuscular junction. Notably, it is also frequently associated with thymic pathology. This study explores the relationship between MG and DNA viruses in the thymus, employing targeted next-generation sequencing and quantitative polymerase chain reaction to analyze thymic tissue samples from both patients with MG and healthy controls. We detected human herpes virus 6B and 7, Epstein-Barr virus, and parvovirus B19 (B19V) across various tissue groups. However, no significant enrichment of these viruses was observed in the thymic tissue of patients with MG.


  • Epstein-Barr Virus in the Cerebrospinal Fluid and Blood Compartments of Patients With Multiple Sclerosis and Controls

    by Joonas Lehikoinen, Katariina Nurmi, Mari Ainola, Jonna Clancy, Janne K. Nieminen, Lilja Jansson, Hanna Vauhkonen, Antti Vaheri, Teemu Smura, Sini M. Laakso, et al.

    Epstein-Barr virus (EBV) infection is a major risk factor of multiple sclerosis (MS). We examined the presence of EBV DNA in the CSF and blood of patients with MS and controls. We analyzed whether EBV DNA is more common in the CSF of patients with MS than in controls and estimated the proportions of EBV-positive B cells in the CSF and blood. CSF supernatants and cells were collected at diagnostic lumbar punctures from 45 patients with MS and 45 HLA-DR15 matched controls with other conditions, all participants were EBV seropositive. Cellular DNA was amplified by Phi polymerase targeting both host and viral DNA, and representative samples were obtained in 28 cases and 28 controls. Nonamplified DNA from CSF cells (14 cases, 14 controls) and blood B cells (10 cases, 10 controls) were analyzed in a subset of participants. Multiple droplet digital PCR (ddPCR) runs were performed per sample to assess the cumulative EBV positivity rate. To detect viral RNA as a sign of activation, RNA sequencing was performed in blood CD4-positive, CD8-positive, and CD19-positive cells from 21 patients with MS and 3 controls. One of the 45 patients with MS and none of the 45 controls were positive for EBV DNA in CSF supernatants (1 mL). CSF cellular DNA was analyzed in 8 independent ddPCRs: EBV DNA was detected at least once in 18 (64%) of the 28 patients with MS and in 15 (54%) of the 28 controls (p = 0.59, Fisher test). The cumulative EBV positivity increased steadily up to 59% in the successive ddPCRs, suggesting that all individuals would have reached EBV positivity in the CSF cells, if more DNA would have been analyzed. The estimated proportion of EBV-positive B cells was >1/10,000 in both the CSF and blood. We did not detect viral RNA, except from endogenous retroviruses, in the blood lymphocyte subpopulations. EBV-DNA is equally detectable in the CSF cells of both patients with MS and controls with ddPCR, and the probabilistic approach indicates that the true positivity rate approaches 100% in EBV-positive individuals. The proportion of EBV-positive B cells seems higher than previously estimated.


  • Open Access

    Cultured lymphocytes’ mitochondrial genome integrity is not altered by cladribine

    by Elina Järvinen, Fumi Suomi, James B Stewart, Dimitri Guala, Miko Valori, Lilja Jansson, Janne Nieminen, Thomas G McWilliams, Pentti J Tienari

    Cladribine tablets are a treatment for multiple sclerosis with effects on lymphocytes, yet its mode of action has not been fully established. Here, we analyzed the effects of cladribine on mitochondrial DNA integrity in lymphocytes. We treated cultured human T-cell lines (CCRF-CEM and Jurkat) with varying concentrations of cladribine to mimic the slow cell depletion observed in treated patients. The CCRF-CEM was more susceptible to cladribine than Jurkat cells. In both cells, mitochondrial protein synthesis, mitochondrial DNA copy number, and mitochondrial cytochrome-c oxidase-I mRNA mutagenesis was not affected by cladribine, while caspase-3 cleavage was detected in Jurkat cells at 100 nM concentration. Cladribine treatment at concentrations up to 10 nM in CCRF-CEM and 100 nM in Jurkat cells did not induce significant increase in mitochondrial DNA mutations. Peripheral blood mononuclear cells from eight multiple sclerosis patients and four controls were cultured with or without an effective dose of cladribine (5 nM). However, we did not find any differences in mitochondrial DNA somatic mutations in lymphocyte subpopulations (CD4+, CD8+, and CD19+) between treated versus nontreated cells. The overall mutation rate was similar in patients and controls. When different lymphocyte subpopulations were compared, greater mitochondrial DNA mutation levels were detected in CD8+ (P = 0.014) and CD4+ (P = 0.038) as compared to CD19+ cells, these differences were independent of cladribine treatment. We conclude that T cells have more detectable mitochondrial DNA mutations than B cells, and cladribine has no detectable mutagenic effect on lymphocyte mitochondrial genome nor does it impair mitochondrial function in human T-cell lines.


  • Open Access

    The shared ancestry between the C9orf72 hexanucleotide repeat expansion and intermediate-length alleles using haplotype sharing trees and HAPTK

    by Osma S. Rautila, Karri Kaivola, Harri Rautila, Laura Hokkanen, Jyrki Launes, Timo E. Strandberg, Hannu Laaksovirta, Johanna Palmio, Pentti J. Tienari

    The C9orf72 hexanucleotide repeat expansion (HRE) is a common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The inheritance is autosomal dominant, but a high proportion of cases are sporadic. One possible explanation is de novo expansions of unstable intermediate-length alleles (IAs). Using haplotype sharing trees (HST) with the novel haplotype analysis tool kit (HAPTK), we derived majority-based ancestral haplotypes of HRE carriers and discovered that IAs containing ≥18-20 repeats share large haplotypes in common with the HRE. Using HSTs of HRE and IA carriers, we demonstrate that the longer IA haplotypes are largely indistinguishable from HRE haplotypes. These analysis tools allow physical understanding of the haplotype blocks shared with the ancestral haplotype. Our results demonstrate that the haplotypes with longer IAs belong to the same pool of haplotypes as the HRE and suggest that longer IAs represent potential premutation alleles.